Pulmonary
Antibiotics
Mycobacterium abscessus
line probe assay
oral macrolide
pulmonary disease
Journal
International journal of mycobacteriology
ISSN: 2212-554X
Titre abrégé: Int J Mycobacteriol
Pays: India
ID NLM: 101615660
Informations de publication
Date de publication:
Historique:
entrez:
12
3
2021
pubmed:
13
3
2021
medline:
16
10
2021
Statut:
ppublish
Résumé
Pulmonary disease due to Mycobacterium abscessus (Mab) has become an increasing cause of health concern, particularly among individuals infected with nontuberculous mycobacteria. Since Mab is intrinsically resistant to many antibiotics, it is very challenging to treat patients with symptomatic disease. In this case series, we report four patients with symptomatic pulmonary Mab who had prior history of antituberculosis treatment intake and declared cured at the end of treatment. The current episode was confirmed to be due to Mab infection by molecular and clinical diagnosis and received species specific-antibiotics therapy. All were periodically monitored for the sputum smear and culture conversions throughout the treatment period. The clinical course was variable though all received similar antibiotic regimen and showed varied treatment outcomes. The time of diagnosis and the treatment outcome indicate that a better understanding of host-pathogen interactions is essential for the successful treatment of pulmonary Mab infection.
Identifiants
pubmed: 33707380
pii: IntJMycobacteriol_2021_10_1_93_310509
doi: 10.4103/ijmy.ijmy_22_21
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-97Déclaration de conflit d'intérêts
None